Home Cart Sign in  
Chemical Structure| 2922-83-0 Chemical Structure| 2922-83-0

Structure of Kynurenine
CAS No.: 2922-83-0

Chemical Structure| 2922-83-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

L-Kynurenine is a metabolite of the amino acid L-tryptophan. L-Kynurenine is an aryl hydrocarbon receptor agonist.

Synonyms: 3-anthraniloyl-Alanine; (S)-Kynurenine; CCRIS 4425

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Kynurenine

CAS No. :2922-83-0
Formula : C10H12N2O3
M.W : 208.21
SMILES Code : O=C(O)[C@@H](N)CC(C1=CC=CC=C1N)=O
Synonyms :
3-anthraniloyl-Alanine; (S)-Kynurenine; CCRIS 4425
MDL No. :MFCD00069912
InChI Key :YGPSJZOEDVAXAB-QMMMGPOBSA-N
Pubchem ID :161166

Safety of Kynurenine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
K562 human chronic myeloid leukemia cells 50 µM 16 h To study the effect of LKU on T cell cytotoxicity, it was found that LKU reduced the cytotoxic activity of T cells. PMC10416736
Primary human CD3-positive T cells 50 µM 16 h To study the effect of LKU on HIF-1 activity, it was found that VEGF mRNA levels were significantly upregulated in the presence of IDO1 inhibitors. PMC10416736
Jurkat T cells 50 µM 16 h To study the effect of LKU on HIF-1 activity, it was found that VEGF mRNA levels were significantly increased in Jurkat T cells. PMC10416736
WT-3ab Wilms’ tumor cells 50 µM 4 h To study the effect of LKU on intracellular LKU levels, it was found that LKU levels were significantly increased in WT-3ab cells. PMC10416736
LN18 human glioblastoma cells 50 µM 4 h To study the effect of LKU on intracellular LKU levels, it was found that LKU levels were not significantly increased in LN18 cells. PMC10416736
MCF-7 human breast cancer cells 50 µM 4 h To study the effect of LKU on HIF-1α nuclear translocation, it was found that LKU downregulated HIF-1α nuclear levels under hypoxic conditions. PMC10416736
Murine CD4+ T cells 1 mM 3 h To investigate the effect of D-kynurenine on murine T cell metabolism, found it increased fatty acid β-oxidation leading to fatty acid depletion. PMC8652007
Human CD4+ T cells 1 mM 3 days To evaluate the effect of D-kynurenine on T cell proliferation and apoptosis, results showed 1 mM D-kynurenine inhibits T cell proliferation through apoptosis. PMC8652007
Primary human NK cells 200 μM 48 h To investigate the effect of L-KYN on primary human NK cell viability, it was found that L-KYN significantly increased the proportion of primary human NK cell death PMC9976385
NK-92 cells 200 μM 24 or 48 h To investigate the effect of L-KYN on NK-92 cell viability, it was found that L-KYN significantly increased the proportion of NK-92 cell death PMC9976385
Arabidopsis thaliana seedlings 0.01 μM -1 mM 3 days To evaluate the inhibitory effect of Kyn on root growth in Arabidopsis thaliana seedlings. The results showed that Kyn significantly inhibited root growth in a concentration-dependent manner PMC3246337
conventional dendritic cells (cDCs) 50 μM 24 h To evaluate the ability of L-Kynurenine to induce IDO1 expression and TGF-β production in LPS-primed cDCs. Results showed that L-Kynurenine significantly enhanced IDO1 expression and TGF-β production, an effect dependent on AhR activation. PMC7081078

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice B6/Rag1-/- colitis model Dietary supplementation 300 mg/kg 10 days To evaluate the protective effect of D-kynurenine on autoimmune colitis, results showed D-kynurenine protected mice from colitis in an AhR-dependent manner. PMC8652007
HIL-15 NOG mice Humanized CDX tumor model Subcutaneous injection 4 μg Every other day for 14 days To investigate the effect of L-KYN on NK cells in the tumor microenvironment, it was found that L-KYN significantly reduced the number of NK cells in tumor tissues and increased their death rate PMC9976385
Mice Tauopathy mouse model Intraperitoneal injection 33 mg/10 ml/kg Single injection, sacrificed after 3 hours To investigate the effects of Kynurenine on neuroinflammation and neurodegeneration in a tauopathy mouse model. Results showed that Kynurenine levels were elevated in the brains of tauopathy model mice, and Amino LP7 treatment significantly reduced these levels, suppressing neuroinflammation and brain atrophy. PMC8535828
Mice Cardiac arrest model Intravenous injection 20 mg/kg Single dose, observed for 7 days To evaluate the effects of the kynurenine pathway on brain injury after cardiac arrest. Results showed that IDO?/? mice had significantly higher survival rates and better neurological function compared to wild-type mice, and kynurenine pathway activation was associated with brain injury. PMC10566599

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.80mL

0.96mL

0.48mL

24.01mL

4.80mL

2.40mL

48.03mL

9.61mL

4.80mL

References

 

Historical Records

Categories